-

Zoetis to Participate in the Stifel 2022 Jaws and Paws Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2022 Jaws and Paws Conference on Wednesday, June 1, 2022. Glenn David, Executive Vice President and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance, will represent the company and respond to questions from analysts. He is scheduled to present at 4:10 p.m. ET.

Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website after the event.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide -- from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more information, visit www.zoetis.com.

ZTS-COR
ZTS-IR
ZTS-FIN

Contacts

Media:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investor:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Versions
$Cashtags

Contacts

Media:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investor:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

More News From Zoetis Inc.

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

PARSIPPANY, N.J.--(BUSINESS WIRE)--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections...

Zoetis Appoints Iris Knobloch to its Board of Directors

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of...

Zoetis Declares Fourth Quarter 2026 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a leg...
Back to Newsroom